Company CRISPR/Cas Technology Sample Clauses

Company CRISPR/Cas Technology. Subject to any existing licenses between Casebia or Casebia Therapeutics, LLC and a Third Party as listed in Schedule C, all Company CRISPR/Cas Technology will be co-owned by Bayer and CRISPR. Casebia hereby assigns to each of CRISPR and Bayer an undivided joint ownership interest in the Company CRISPR/Cas Technology, subject to the terms of any existing licenses between Casebia or Casebia Therapeutics, LLC and a Third Party, and the terms of the Amended and Restated Intellectual Property Management Agreement. CRISPR hereby grants to Bayer (i) an exclusive, sublicensable, license under CRISPR’s joint interest in the Company CRISPR/Cas Patents, Patentable Company CRISPR/Cas Know-How and any Patents claiming or Covering such Patentable CRISPR/Cas Know-How, in each case, for Non-Human Therapeutic Uses and (ii) a non-exclusive, sublicensable license under CRISPR’s joint interest in the Company CRISPR/Cas Patents, Patentable Company CRISPR/Cas Know-How and any Patents claiming or Covering such Patentable CRISPR/Cas Know-How, in each case, for Human Therapeutic Uses in the Bayer Fields. Bayer hereby grants to CRISPR (x) an exclusive, sublicensable license under Bayer’s joint interest in the Company CRISPR/Cas Patents, Patentable Company CRISPR/Cas Know-How and any Patents claiming or Covering such Patentable CRISPR/Cas Know-How, in each case, for Human Therapeutic Uses (other than the Bayer Fields) and (y) a non-exclusive, sublicensable license under Bayer’s joint interest in the Company CRISPR/Cas Patents, [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Patentable Company CRISPR/Cas Know-How and any Patents claiming or Covering such Patentable CRISPR/Cas Know-How, in each case, for Human Therapeutic Uses in the Bayer Fields. For the avoidance of doubt, Bayer and CRISPR acknowledge and agree that each, as a joint owner thereof, is free to use the Company CRISPR/Cas Technology, for any purpose outside of the scope of the exclusive licenses granted hereunder, including the right to license and sublicense or otherwise exploit, transfer or encumber its ownership interest in such Company CRISPR/Cas Technology, without any accounting or obligation to (financial or otherwise), or consent required from, the other party. For clarity, Bayer and CRISPR are free to use the Unpatentable Company CRISPR/Cas Know-How for any purpose, including the rig...
Sample 1
AutoNDA by SimpleDocs

Related to Company CRISPR/Cas Technology

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Joint Technology The Parties agree that, in order to effectuate the provisions of Section 4.4.2, subject to any exclusive licenses granted hereunder, (a) the non-use provisions of this Article 9 shall not apply to each Party’s use of Joint Technology, and (b) each Party may disclose the Joint Technology to Third Parties who are under terms of confidentiality no less strict than those contained in this Agreement.

  • New Technology If New Technology becomes available from any source, including Supplier, then KP may evaluate and contract with any supplier so that KP will have access to New Technology at all times. If Supplier cannot offer New Technology at comparable or lower prices, KP may either (a) amend contract pricelist to add Supplier's New Technology at a mutually agreed-upon price; or (b) contract with other suppliers for New Technology. Regardless of whether New Technology is added to this Agreement, Supplier and KP will negotiate in good faith to equitably adjust the pricing for any current Product under this Agreement affected by the New Technology.

  • Technology For purposes of this Agreement, “Technology” means all Software, information, designs, formulae, algorithms, procedures, methods, techniques, ideas, know-how, research and development, technical data, programs, subroutines, tools, materials, specifications, processes, inventions (whether or not patentable and whether or not reduced to practice), apparatus, creations, improvements and other similar materials, and all recordings, graphs, drawings, reports, analyses, and other writings, and other embodiments of any of the foregoing, in any form or media whether or not specifically listed herein. Further, for purposes of this Agreement, “Software” means any and all computer programs, whether in source code or object code; databases and compilations, whether machine readable or otherwise; descriptions, flow-charts and other work product used to design, plan, organize and develop any of the foregoing; and all documentation, including user manuals and other training documentation, related to any of the foregoing.

  • Background IP Each Party will own all right, title and interest in its Background IP.

  • Patent Rights The term “

  • Licensed Patent Rights The term “Licensed Patent Rights” shall mean rights arising out of or resulting from:

  • Licensed Software Section 3.17(f).......................................27

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!